Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22750600 | 0.77 | ADORA3 (0.48) | ADORA3ADORA1ADORA2ASLC6A2 | |
| SCHEMBL22757352 | 0.76 | ADORA3 (0.54) | ADORA3ADORA1ADORA2AHRH2HTR5A | |
| SCHEMBL22757377 | 0.73 | ADORA3 (0.58) | ADORA3ADORA1ADORA2AHRH2HTR5A | |
| SCHEMBL22757421 | 0.73 | ADORA3 (0.55) | ADORA3ADORA1ADORA2A | |
| SCHEMBL22757475 | 0.70 | ADORA3 (0.40) | ADORA3ADORA1ADORA2A | |
| SCHEMBL22757470 | 0.69 | ADORA1 (0.41) | ADORA3ADORA1ADORA2ASLC6A2 | |
| SCHEMBL22757323 | 0.69 | ADORA1 (0.47) | ADORA3ADORA1ADORA2ASLC6A2 | |
| SCHEMBL22757354 | 0.68 | ADORA1 (0.48) | ADORA3ADORA1ADORA2ASLC6A2 | |
| SCHEMBL29573875 | 0.68 | HRH2 (0.53) | ADORA3ADORA1ADORA2AHRH2HTR5A | |
| SCHEMBL29574073 | 0.67 | HTR2B (0.51) | ADORA3ADORA1ADORA2AHRH2HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020247546-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. (US) | 2020-12-10 | — | — | WO | disclosed |